The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 8th 2024
An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Plaque Psoriasis Drug Candidate Shows Positive Top-Line Results in First of Two Phase III Studies
October 31st 2014Amgen has released positive top-line results from the first of two Phase III studies of ABP 501, its candidate for the treatment of moderate-to-severe plaque psoriasis that is being developed as a biosimilar to adalimumab.
First Studies Show Which Genes Respond to PsA Treatment
October 30th 2014For the first time, we know which genes are altered by treatments for psoriatic arthritis (PsA), and how. One study compares etanercept and methotrexate. Another looks at how infliximab works in PsA and rheumatoid arthritis, showing conclusively that the two conditions are different.
Why Rheumatologists Should Be Excited About the New RISE Registry
October 28th 2014Just as a rising tide lifts all boats, the American College of Rheumatology's aptly named new registry should boost overall outcomes in rheumatic disease, if enough clinicians join. A rheumatologist with informatics credentials hopes its ease of use (and benefits) will encourage wide adoption.
FDA Re-Approves Formerly Withdrawn Opioid Shown Effective Against OA Pain
October 20th 2014Pfizer expects to release Embeda (morphine sulfate and naltrexone hydrochloride), approved in 2009 based on osteoarthritis studies but withdrawn by another firm in 2011 due to concerns over abuse, sometime early next year.